ZymoGenetics, Inc. Reports Favorable Survival Data from IL-21 Phase 2a Clinical Trial in Melanoma

Published: Sep 29, 2010

SEATTLE--(BUSINESS WIRE)--ZymoGenetics, Inc. (NASDAQ:ZGEN) today announced positive survival data from a Phase 2a clinical trial in metastatic melanoma with recombinant Interleukin 21 (IL-21) as a single agent. Median overall survival was 12.4 months, and the percentage of patients surviving at 12 months was 53%.

Back to news